Transitional polytherapy: Tricks of the trade for monotherapy to monotherapy AED conversions

Current Neuropharmacology

Volumn 7, Issue 2, 2009, Pages 83-95

  Garnett, William R ^a   St Louis, Erik K ^b   Henry, Thomas R ^c   Bramley, Thomas ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d XCENDA   (United States)

Author keywords

Antiepileptic drugs; Conversion; Epilepsy; Monotherapy; Pharmacokinetics; Polytherapy; Titration

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; BANZEL; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEPAKOTE ER; ETIRACETAM; FELBAMATE; GABAPENTIN; GABATRIL; HARKOSERIDE; HYPOCHOLESTEROLEMIC AGENT; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTEK; PHENYTOIN; PREGABALIN; RUFINAMIDE; SODIUM CHANNEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; WARFARIN; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; APLASTIC ANEMIA; BLEEDING; BLURRED VISION; CHANNEL GATING; CONSENSUS DEVELOPMENT; DIPLOPIA; DISEASE EXACERBATION; DROWSINESS; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY FAILURE; LETHARGY; LIVER DISEASE; LIVER DYSFUNCTION; LIVER INJURY; MEDICAL EXPERT; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; POLYPHARMACY; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; STEVENS JOHNSON SYNDROME; TERATOGENICITY; UNSPECIFIED SIDE EFFECT;

EID: 70349684925     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015909788848884     Document Type: Review

References (51)

1. Abou-Khalil, B. (2008) Levetiracetam in the treatment of epilepsy. Neuropsychiatr. Dis. Treat., 4(3), 507-523.
2. Albani, F., Riva, R., Baruzzi, A. (1995) Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry, 28(6), 235-244.
3. Arroyo, S. (2007) Rufinamide. Neurotherapeutics, 4(1), 155-162.
4. Artama, M., Auvinen, A., Raudaskoski, T., Isojarvi, I, Isojarvi, J. (2005) Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology, 64(11), 1874-1878.
5. Biton, V. (2007) Clinical pharmacology and mechanism of action of zonisamide. Clin, Neuropharmacol., 30(4), 230-40.
6. Booth, D., Evans, D.J. (2004) Anticonvulsants for neonates with seizures. Cochrane Database Syst. Rev., (3), doi: 10.1002/ 14651858.CD004218.pub2.
7. Brodie, M.J., Perucca, E., Ryvlin, P., Ben-Menachem, E., Meencke, H.J. (2007) Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology, 68(6), 402-408.
8. Christensen, J., Petrenaite, V., Atterman, J., Sidenius, P., Ohman, I., Tomson, T., Sabers, A. (2007) Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia, 28(3), 484-489.
9. Cramer, J.A., Russel,l M.L. (1988) Compliance in epilepsy: strategies to enhance adherence to a medical regimen. Epilepsy Res. Suppl., 1, 163-175.
10. Doty, P., Rudd, G.D., Stoehr, T., (2007) Thoma. Lacoasmide. Neurotherapeutics, 4(1), 145-148.
11. Dreifuss, F.E., Langer, D.H. (2007) Hepatic considerations in the use of antiepileptic drugs. Epilepsia, 28(Suppl 2), S23-29.
12. Dworkin, R.H., Kirkpatrick, P. (2005) Pregabalin. Nat. Rev. Drug Discov., 4, 455-456.
13. Farooq, M.U., Bhatt, A., Majid, A., Gupta, R., Khasnis, A., Kassab, M.Y. (2009) Levetiracetam for managing neurologic and psychiatric disorders. Am. J. Health Syst. Pharm., 66(6), 541-561.
14. Fattore, C., Cipolla, G., Gatti, GL., Limido, G.L., Sturn, Y., Bernasconi, C., Perucca, E. (1999) Induction of ethinylestradiol and levorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia, 40, 783-787.
15. Ferrell, P.B. Jr., McLeod, H.L. (2008) Carbamazepine, HLA-B* 1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9(10), 1543-1546.
16. Fitton, A., Goa, K.L. (1995) Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs, 50(4), 691-713.
17. Franciotta, D., Kwan, P., Perucca, E. (2009) Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr. Opin. Neurol., 22(2), 144-149.
18. French, J.A., Kanner, A.M., Bautista J, Abou-Khalil, B., Browne, T., Harden, C.L., Theodore, W.H., Bazil, C., Stern, J., Schachter, S.C., Bergen, D., Hirtz, D., Montouris, G.D., Nespeca, M., Gidal, B., Marks, W.J. Jr., Turk, W.R., Fischer, J.H., Bourgeois, B., Wilner, A., Faught, R.E., Sachdeo, R.C, Beydoun, A., Glauser, T.A. (2004) Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 62, 1261-1273.
19. Garnett, W.R. (2000) Clinical pharmacology of topiramate: a review. Epilepsia, 41(Suppl 1), S61-5.
20. Gilliam, F.G., Fessler, A.J., Baker, G., Vahle, V., Carter, J., Attarian, H. (2004) Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology, 62(1), 23-27.
21. Goldsmith, D.R., Wagstaff, A.J., Ibbotson, T., Perry, C.M. (2003) Lamotrigine: a review of its use in bipolar disorder. Drugs, 63(19), 2029-2050.
22. Gram, L. (2007) Tiagabine: A novel drug with a GABAergic mechanism of action. Epilepsia, 35(Supp 5), S85-87.
23. Jones, G.L., Wimbish, G.H., McIntosh, W.E. (2006) Phenytoin: basic and clinical pharmacology. Med. Res. Rev., 3(4), 383-434.
24. Kothare, S.V., Kaleyias, J. (2008) Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin. Drug Metab. Toxicol., 4(4), 493-506.
25. Kwan, P., Brodie, M.J. Early identification of refractory epilepsy. (2000) N. Engl. J. Med., 342, 314-319.
26. Kwan, P., Brodie, M.J. (2000) Epilepsy after the first drug fails: substitution or add-on? Seizure 9, 464-468.
27. Kwan, P., Brodie, M.J. (2001) Effectiveness of first antiepileptic drug. Epilepsia, 42, 1255-1260.
28. Kwan, P., Brodie, M.J. (2004) Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia, 45(9), 1141-1149.
29. Levy, R.H., Wurden, C.J. (1995) Carbamazepine: interactions with other drugs. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Eds. Antiepileptic drugs. 4th ed. Raven Press: New York, pp. 543-554.
30. Löscher, W. (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs, 16(10), 669-94.
31. Lynch, B.A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S.M., Matagne, A., Fuks, B. (2004) "The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam". Proc. Natl. Acad. Sci. USA, 101(26), 9861-9866.
32. Mazza, M., Della Marca, G., Di Nicola, M.,Martinotti, G., Gino, P., Janiri, L., Bria, P., Mazza, S. (2007) Oxcarbazepine improves mood in Patients with epilepsy. Epilepsy Behav., 10(3), 397-401.
33. Palmer, K.J., McTavish, D. (1993) Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs, 45(6), 1041-1065.
34. Pellock, J., Faught,E., Leppik, I., Shinnar, S., Zuppanc, M.L. (2006) Felbamate: consensus of current clinical experience. Epilepsy Res., 71(2), 89-101.
35. Privatera, M.D. (1997) Clinical rules for phenytoin dosing. Ann. Pharmacother., 27(10), 1164-1173.
36. Privatera, M.D., Brodie, M.J., Mattson, R.H., Chadwick, D.W., Neto, W., Wang, S., EPMN 105 Study Group (2003) Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand., 107(3), 165-175.
37. Rettie, A.E., Rettenmeier, A.W., Howald, W.N., Baillie, T.A. (1987) Cytochrome P-450 - catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science, 235(4791), 890-893.
38. Rose, M.A., Kam, P.C. (2002) Gabapentin: pharmacology and its use in pain management. Anaesthesia, 57(5), 451-462.
39. Sabers, A., Öhman, I., Christensen, J., Tomson, T. (2003) Oral contraceptives reduce lamotrigine plasma levels. Neurology, 61(4), 570-571.
40. Schachter, S.C. (1999) Oxcarbazepine: current status and clinical applications. Exp. Opin. Investig. Drugs, 8, 1-10.
41. Shank, R.P., Gardock,i J.F., Streeter, A.J, Maryanoff, B.E. (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia, 41(Suppl 1), S3-9.
42. Shorvon, S. (2000) Oxcarbazepine: a review. Seizure, 9(2), 75-79.
43. Sidhu, J., Job, S., Singh, S., Philipson, R. (2006) The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol., 61(2), 191-199.
44. Sills, G.J. (2006) The mechanisms of action of gabapentin and pregabalin. Curr. Opin. Pharmacol., 6(1), 108-113.
45. StLouis, E.K., Gidal, B.E., Henry, T.R., Kaydanova, Y., Krumholz, A., McCabe, P.H., Montouris, G.D., Rosenfeld, W.E., Smith, B.J., Stern, J.M., Waterhouse, E.J., Schulz, R.M., Garnett, W.R., Bramley, T. (2007) Conversions between monotherapies in epilepsy: expert consensus. Epilepsy Behav., 11, 222-234.
46. Surges, R. (2008) Review: is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther. Adv. Neurol. Disord., 1(1), 13-24.
47. Tran, T.A., Leppik, I.E., Blesi. K., Sathanandan, S.T., Remmel, R. (2002) Lamotrigine clearance during pregnancy. Neurology, 59, 251-255.
48. Vajda, F.J., Eadie, M.J. (2005) Maternal valproate dosage and foetal malformations. Acta Neurol. Scand., 112(3), 137-143.
49. Walker, M.C. (2002) The mechanism of action of Tiagabine. Rev. Contemporary Pharmacother., 12(5), 213-223.
50. Wyszynski, D.F., Nambisan, M., Surve, T., Alsdorf, R.M., Smith, C.R., Holmes, L.B. (2005) Antiepileptic drug pregnancy registry: increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology, 64(6), 961-965.
51. Yuen, A.W., Land, G., Weatherly, B.C., Peck, A.W. (1992) Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Clin. Pharmacol., 33(5), 511-513.